FDA Warns Biogen On Tysabri, Gilead On Truvada Promotions
April 07 2010 - 12:16PM
Dow Jones News
The Food and Drug Administration said Wednesday a promotional
webcast involving the multiple sclerosis drug Tysabri was "false or
misleading" because it minimized the risk of a serious brain
infection.
Tysabri is sold jointly by Elan Corp. (ELN) and Biogen Idec
Corp. (BIIB) to treat multiple sclerosis and Crohn's disease. In a
March 25 letter sent to Biogen Idec, the FDA also cited the company
for failing to submit the webcast to the agency for review 30 days
prior to using the material.
Separately, the agency cited Gilead Sciences Inc. (GILD) for a
print advertisement involving its HIV drug Truvada. In a March 26
letter to Gilead, the FDA said the advertisement was "false or
misleading" because it overstated the effectiveness of the products
and minimized the risks associated with the drug.
Both letters were posted to the FDA's Web site on Wednesday.
-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294;
jennifer.corbett@dowjones.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024